Creabilis
About
Creabilis, a specialty pharmaceutical company focused on dermatology, discovers and develops new medicines for a range of skin disorders.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $20M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2003
- Number Of Employee
- 1 - 10
- Operating Status
- Close
Creabilis is an emerging European specialty pharmaceutical company focused on dermatology. Creabilis discovers, develops and commercialises new medicines for a range of skin disorders, - an area of significant unmet medical need and high commercial potential.Creabilis has an exceptional track record in dermatological research and has used this experience to generate a rich pipeline of clinical and pre-clinical drug candidates that the company will market directly or in partnership. The most advanced product is CT327 for the treatment of psoriasis. CT327 will enter Phase II clinical trials in 2009. Creabilis' pipeline also includes a number of pre-clinical drug candidates arising from its ground breaking drug discovery programmes.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 4, 2011 | Series B | $20M | 1 |
Abbott Biotech Ventures
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Abbott Biotech Ventures
|
Yes | Series B |
